Company profilePharmaceutical#51 of 1,318 in Pakistan✓ No DRAP alerts

Pharmatec Pakistan (Pvt.) Limited

Pharmaceutical company · 238 brands · 225 molecules

Ranked #27 of 112 companies in Blood Glucose Lowering Drugs, Excluding Insulin

238 registered products 66 pharmaceutical brands 225 distinct molecules 0 DRAP alerts

Company overview

238
registered products
66
pharmaceutical brands
225
distinct molecules
12
therapeutic classes
0
DRAP alerts

Pharmatec Pakistan (Pvt.) Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 238 product registrations across 225 distinct molecules. It is the 51st largest registrant in Pakistan by product count, and ranks 27th of 112 in Blood Glucose Lowering Drugs, Excluding Insulin. Its portfolio is concentrated in Blood Glucose Lowering Drugs, Excluding Insulin and Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Pharmatec

211 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

142
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202558
202684

Top molecules by brand count

Paracetamol9 brands
Amlodipine6 brands
Loratadine6 brands
Ribavirin5 brands
Diclofenac5 brands
Artemether5 brands
Omeprazole4 brands

Therapeutic classes

Blood Glucose Lowering Drugs, Excluding Insulin · 6Other Beta-Lactam, Cephalosporins & Penems · 5Quinolone Antibacterials · 5Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 5Antihistamines For Systemic Use · 5Pain Management · 4Cardiac Care · 4Lipid Modifying Agents · 4Antiinflammatory And Antirheumatic Products · 4Antidepressants · 4Angiotensin-Ii Antagonists, Combinations · 4Neuro · 4

Conditions treated

Cold/Cough/Flu · 2Anxiety/Depression/Insomnia · 2Muscle Relaxant/Spasm · 1Oral Agents · 1High Cholestrol · 1Conventional Agents · 1Oncology · 1Pain Killers · 1Hypertension · 1Heart Failure · 1Ulcer/Reflux/Flatulence/Acidity · 1Expectorant · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official162 products · Rs 74.94 – Rs 5,177.34
DVAGO57 products · Rs 18.9 – Rs 689.7
Servaid29 products · Rs 56.16 – Rs 4,500
Median across source: Rs 303.6

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SEARLE PAKISTAN (PVT.) LTD. holds 167 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline
GETZ PHARMA PAKISTAN (PVT) LTD. holds 208 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
Atco Pharma International (Pvt) Ltd holds 181 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline

Get the full profile for Pharmatec

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.